Get the Stockscreener App
15.12
2.51%
-0.39
After Hours:
15.12
Kalvista Pharmaceuticals Inc stock is traded at $15.12, with a volume of 473.24K.
It is down -2.51% in the last 24 hours and down -7.75% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$15.51
Open:
$15.7
24h Volume:
473.24K
Relative Volume:
0.37
Market Cap:
$764.26M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-4.0976
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+5.00%
1M Performance:
-7.75%
6M Performance:
+23.43%
1Y Performance:
+62.06%
1-Day Range:
$14.90
$15.70
1-Week Range:
$14.41
$15.70
52-Week Range:
$8.9915
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.12 | 783.97M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN
Responsive Playbooks and the KALV Inflection - Stock Traders Daily
Aug Sentiment: Is KalVista Pharmaceuticals Inc subject to activist investor interestPortfolio Value Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results - Yahoo Finance
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade - Yahoo Finance
KalVista Pharmaceuticals (KALV) Stock Analysis: Uncovering a 112% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Is KalVista Pharmaceuticals Inc forming higher highs and higher lowsJuly 2025 Recap & Safe Capital Growth Tips - baoquankhu1.vn
Quarterly Earnings: Is Intelligent Living Application Group Inc stock overvalued or fairly pricedAnalyst Downgrade & High Accuracy Swing Trade Signals - baoquankhu1.vn
What is KalVista Pharmaceuticals Incs P E ratio telling usMarket Risk Report & Technical Confirmation Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV) - The Globe and Mail
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV - TipRanks
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect? - MSN
Understanding the Setup: (KALV) and Scalable Risk - Stock Traders Daily
Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Multicare and KalVista collaboration in Latin America - The Pharma Letter
Multicare, KalVista to expand oral HAE treatment in Latin America - Mexico Business News
Aug Macro: What analysts say about KalVista Pharmaceuticals Inc stockQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Recap Report: What chart patterns are forming on KalVista Pharmaceuticals IncWeekly Profit Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - sharewise.com
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
Analysts Expect Breakeven For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Before Long - 富途资讯
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com Australia
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):